Ruocai Xu

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Josep M. Llovet, Masatoshi Kudo, Philippe Merle et al. · The Lancet Oncology · 2023 · 421 citations · Full text

Medicine, Oncology, Pharmacology +12

Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial

Shukui Qin, Zhendong Chen, Weijia Fang et al. · Journal of Clinical Oncology · 2022 · 189 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Phase III HEAT Study Adding Lyso-Thermosensitive Liposomal Doxorubicin to Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma Lesions

Won Young Tak, Shi-Ming Lin, Yijun Wang et al. · Clinical Cancer Research · 2017 · 163 citations

Medicine, Oncology, Pharmacology +14

Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.

Shukui Qin, Zhendong Chen, Weijia Fang et al. · Journal of Clinical Oncology · 2022 · 111 citations

Pharmacy, Oncology, Pharmacotherapy +17

Combination Therapy With Sorafenib and Radiofrequency Ablation for BCLC Stage 0–B1 Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study

Xiaobin Feng, Ruocai Xu, Xilin Du et al. · The American Journal of Gastroenterology · 2014 · 79 citations

Medicine, Oncology, Pharmacotherapy +17